"Direct vaccination cannot prevent diseases that affect neonates in the first days of live. Group B Streptococcus (GBS) is the major cause of neonatal septicemia nd meningitis affecting up to one in every thousand live births. Over 80% of cases occur in the first 7 days after birth and the remaining 20% of disease occurs between 8-90 days after birth. Studies carried out in the USA indicate that high titres of maternal antibody to GBS capsular polysaccharides (CPS) correlate with reduced risk of diseases in neonates suggesting that maternal immunization may be an effective strategy for delivery of a protective immune response to the child in this early period. The overall objective of this proposal is to design immunization strategies capable of inducing strong durable and placentally transferable protective immune responses agains GBS in women in order to fill this gap in early infancy when direct immunization is not possible.Starting with the genome sequenceof 8 strains of GBS, Novartis scientist"@en . "Desing of a vaccine to immunize neonates against GBS infections through a durable maternal immune response"@cs . "Desing of a vaccine to immunize neonates against GBS infections through a durable maternal immune response"@en . "2008-01-01+01:00"^^ . . . . "1"^^ . . "Direct vaccination cannot prevent diseases that affect neonates in the first days of live. Group B Streptococcus (GBS) is the major cause of neonatal septicemia nd meningitis affecting up to one in every thousand live births. Over 80% of cases occur in the first 7 days after birth and the remaining 20% of disease occurs between 8-90 days after birth. Studies carried out in the USA indicate that high titres of maternal antibody to GBS capsular polysaccharides (CPS) correlate with reduced risk of diseases in neonates suggesting that maternal immunization may be an effective strategy for delivery of a protective immune response to the child in this early period. The overall objective of this proposal is to design immunization strategies capable of inducing strong durable and placentally transferable protective immune responses agains GBS in women in order to fill this gap in early infancy when direct immunization is not possible.Starting with the genome sequenceof 8 strains of GBS, Novartis scientist"@cs . "2508"^^ . . "2508"^^ . . "Vaccine; GBS; Streptococcos; Newborns; Passive immunisations"@en . . . . . "0"^^ . "2"^^ . "2010-12-31+01:00"^^ . "0"^^ . "2"^^ . . .